United Therapeutics Corporation $UTHR Shares Sold by WINTON GROUP Ltd

WINTON GROUP Ltd cut its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 82.4% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 2,292 shares of the biotechnology company’s stock after selling 10,752 shares during the quarter. WINTON GROUP Ltd’s holdings in United Therapeutics were worth $1,242,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. California State Teachers Retirement System grew its position in shares of United Therapeutics by 55,526.2% in the second quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock valued at $18,036,953,000 after purchasing an additional 33,229,108 shares during the period. BlackRock Inc. acquired a new stake in United Therapeutics in the 2nd quarter worth about $2,868,735,000. Wellington Management Group LLP grew its holdings in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the period. Jupiter Topco LLC purchased a new stake in United Therapeutics in the 2nd quarter valued at about $450,140,000. Finally, Norges Bank acquired a new position in shares of United Therapeutics during the 4th quarter valued at about $293,418,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $540.15, for a total transaction of $5,401,500.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,195,871.40. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $552.40, for a total transaction of $5,247,800.00. Following the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,379,381.20. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 364,575 shares of company stock worth $191,659,133 over the last three months. 8.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Finally, Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $497.11 on Monday. The business’s 50-day moving average is $520.91 and its two-hundred day moving average is $540.76. The firm has a market capitalization of $21.32 billion, a PE ratio of 17.79, a price-to-earnings-growth ratio of 2.49 and a beta of 0.56. United Therapeutics Corporation has a 12 month low of $396.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the business earned $6.41 earnings per share. The company’s revenue was down 1.9% compared to the same quarter last year. Equities analysts anticipate that United Therapeutics Corporation will post 26.21 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.